Janux Therapeutics (JANX) Non-Current Deffered Revenue (2020 - 2026)

Janux Therapeutics (JANX) has 5 years of Non-Current Deffered Revenue data on file, last reported at $8.7 million in Q1 2026.

• On a quarterly basis, Non-Current Deffered Revenue changed N/A year-over-year to $8.7 million in Q1 2026; TTM through Mar 2026 was $8.7 million, a N/A change from a year earlier, with the FY2022 full-year figure at $2.2 million, up 217.29% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $8.7 million, up from $307000.0 in the prior quarter.
• Over the last five years, Non-Current Deffered Revenue for JANX reached as high as $8.7 million in Q1 2026 and fell as low as $307000.0 in Q2 2023.
• Historically, Non-Current Deffered Revenue has averaged $3.6 million across 3 years, with a median of $3.0 million in 2022.
• Across the five-year window, Non-Current Deffered Revenue soared 217.29% in 2022 and slumped 94.2% in 2023, its largest moves.
• Year by year, Non-Current Deffered Revenue stood at $2.2 million in 2022, then slumped by 86.18% to $307000.0 in 2023, then soared by 2726.06% to $8.7 million in 2026.
• Per Business Quant data, the three most recent Non-Current Deffered Revenue figures were $8.7 million in Q1 2026, $307000.0 in Q2 2023, and $1.4 million in Q1 2023.